• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Vicarious Surgical Announces Election of New Directors

    6/30/25 6:45:00 AM ET
    $GSAT
    $IRIX
    $JNJ
    $MITK
    Telecommunications Equipment
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $GSAT alert in real time by email

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the election of Fuad Ahmad and Joseph Doherty to the Vicarious Surgical Board of Directors at the Company's 2025 Annual Meeting of Stockholders held on June 27, 2025. The Company also announced the departure of Ric Fulop from the Vicarious Surgical Board of Directors effective as of the Annual Meeting.

    "On behalf of the board, I am thrilled to welcome Fuad and Joseph to the Vicarious team. Their decades of experience and insight will be instrumental as we continue our advance towards our clinical trial and the eventual commercialization of our platform" said Adam Sachs, CEO and Co-Founder of Vicarious Surgical. "I would also like to thank Ric for his 5-years of dedicated service and invaluable guidance. His tenure has left a lasting positive impact on the Company."

    Mr. Ahmad has been a partner at FLG Partners, a CEO and CFO consulting practice and board advisory services firm, since 2013. From November 2020 to March 2025, he served as CFO of Iridex Corporation (NASDAQ:IRIX), a medical device company. Prior to that, Mr. Ahmad served as CFO at each of Mitek Systems (NASDAQ:MITK), Vaxart, Inc. (NASDAQ:VXRT), Cutera, Inc. and Telenav, Inc. Prior to joining FLG Partners, he served as CFO of Sezmi Corporation, a Morgenthaler Ventures-backed cloud-based software platform. Prior to his service with Sezmi Corporation, Mr. Ahmad served as Senior Vice President and CFO of Globalstar Inc. (NASDAQ:GSAT), a public company that builds and operates low-earth orbit satellite-based digital telecommunications systems. In this role, Mr. Ahmad was involved in the initial fundraising activities related to building and launching Globalstar's satellite telecommunications system, including its IPO and various public market and private financing initiatives totaling more than $1.5 billion. Mr. Ahmad graduated from Brigham Young University with a Bachelor of Science in Finance.

    Mr. Doherty has served as CEO of the Worcester City Campus Corporation, a not-for-profit corporation whose base corporate purpose is to foster, promote and support the University of Massachusetts since January 2025. Since 2020, Mr. Doherty has served as a teacher at Saint John's High School, and since March 2022, Mr. Doherty has also served as a member of the board of directors of Immertec, a software company that creates immersive and interactive experiences for training in healthcare. From 2021 to 2025, he served as the Director for the BOLT initiative at the Massachusetts Biomedical Initiative (MBI), a nonprofit life science startup incubator. From January 2019 to August 2020, he served as the President of Scapa Healthcare, and from January 2019 to May 2020, he was a member of the board of directors of Scapa Group, a publicly traded company on AIM, a market of the London Stock Exchange plc. There, he oversaw a B2B business focused on developing and manufacturing medical devices and consumer wellness products for global market leaders. From 2015 to 2019, Mr. Doherty served in roles of increasing responsibility, including as President of Olympus Surgical Technologies America, a medical device subsidiary of Olympus Corporation of the Americas. He also spent over 24 years with Johnson & Johnson (NYSE:JNJ) and held various roles with increasing responsibilities, ultimately serving as the Vice President of Integration and Transformation. Mr. Doherty received a Bachelor of Science in Engineering from the United States Military Academy at West Point and a Master of Business Administration from Nichols College.

    About Vicarious Surgical

    Founded in 2014, Vicarious Surgical is a next generation surgical robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company's novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla's Khosla Ventures, Innovation Endeavors, Jerry Yang's AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang's E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.

    Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The Company's actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, including without limitation, statements regarding the Company's expectations for its advancement toward a clinical trial and commercialization, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the ability to maintain the listing of the Company's Class A common stock on the New York Stock Exchange; the approval, commercialization and adoption of the Company's initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product and service development activities; the potential attributes and benefits of the Company's product candidates and services; the Company's ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing license, manufacture, supply and distribution agreements; the Company's ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; economic downturns, political and market conditions and their potential to adversely affect the Company's business, financial condition and results of operations; the Company's intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in the Company's filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250630391787/en/

    Investor Contact

    Marissa Bych

    Gilmartin Group

    [email protected]

    Media Inquiries

    [email protected]

    Get the next $GSAT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GSAT
    $IRIX
    $JNJ
    $MITK

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    Johnson & Johnson
    $JNJ
    7/23/2025Hold → Buy
    Erste Group
    Johnson & Johnson
    $JNJ
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    Johnson & Johnson
    $JNJ
    12/10/2024$166.00Neutral
    BofA Securities
    Johnson & Johnson
    $JNJ
    11/15/2024$190.00Outperform
    Wolfe Research
    Mitek Systems Inc.
    $MITK
    9/4/2024$17.00 → $9.50Buy → Hold
    Jefferies
    Vaxart Inc
    $VXRT
    8/15/2024$4.00Outperform
    Oppenheimer
    Johnson & Johnson
    $JNJ
    7/23/2024$160.00 → $150.00Outperform → Neutral
    Daiwa Securities
    More analyst ratings

    $GSAT
    $IRIX
    $JNJ
    $MITK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GSAT
    $IRIX
    $JNJ
    $MITK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP & Chief Financial Officer Clary Rebecca sold $73,521 worth of Voting Common Stock (2,100 units at $35.01), decreasing direct ownership by 2% to 105,661 units (SEC Form 4)

    4 - Globalstar, Inc. (0001366868) (Issuer)

    9/25/25 6:04:53 PM ET
    $GSAT
    Telecommunications Equipment
    Consumer Discretionary

    Chief Executive Officer Jacobs Paul E converted options into 100,000 units of Voting Common Stock and sold $1,869,086 worth of Voting Common Stock (53,479 units at $34.95), increasing direct ownership by 376% to 58,895 units (SEC Form 4)

    4 - Globalstar, Inc. (0001366868) (Issuer)

    9/25/25 5:52:55 PM ET
    $GSAT
    Telecommunications Equipment
    Consumer Discretionary

    VP & Chief Financial Officer Clary Rebecca was granted 9,524 units of Voting Common Stock and sold $159,457 worth of Voting Common Stock (5,359 units at $29.75), increasing direct ownership by 4% to 107,761 units (SEC Form 4)

    4 - Globalstar, Inc. (0001366868) (Issuer)

    9/15/25 6:16:45 PM ET
    $GSAT
    Telecommunications Equipment
    Consumer Discretionary

    $GSAT
    $IRIX
    $JNJ
    $MITK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Dizon Romeo R bought $1,975 worth of shares (1,450 units at $1.36), increasing direct ownership by 2% to 61,950 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    9/15/25 1:26:20 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $1,682 worth of shares (1,250 units at $1.35), increasing direct ownership by 2% to 60,500 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    9/12/25 11:36:27 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $2,010 worth of shares (1,500 units at $1.34), increasing direct ownership by 3% to 59,250 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    9/11/25 11:30:45 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $GSAT
    $IRIX
    $JNJ
    $MITK
    SEC Filings

    View All

    SEC Form 144 filed by Globalstar Inc.

    144 - Globalstar, Inc. (0001366868) (Subject)

    9/25/25 5:49:59 PM ET
    $GSAT
    Telecommunications Equipment
    Consumer Discretionary

    Vicarious Surgical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Vicarious Surgical Inc. (0001812173) (Filer)

    9/25/25 4:15:25 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vicarious Surgical Inc. (0001812173) (Filer)

    9/23/25 5:06:03 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    $GSAT
    $IRIX
    $JNJ
    $MITK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Guggenheim with a new price target

    Guggenheim upgraded Johnson & Johnson from Neutral to Buy and set a new price target of $206.00

    9/23/25 8:13:07 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson upgraded by Erste Group

    Erste Group upgraded Johnson & Johnson from Hold to Buy

    7/23/25 8:55:43 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00

    5/13/25 8:56:13 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GSAT
    $IRIX
    $JNJ
    $MITK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Autonomous Defense Networks Grow as Approximately $28B Investment Wave Transforms Military Communications

    USA News Group News Commentary Issued on behalf of VisionWave Holdings, Inc. VANCOUVER, BC, Sept. 30, 2025 /CNW/ -- USA News Group News Commentary – Defense tech funding surged to approximately $28 billion in 2025 as venture capital investment in autonomous systems and communications technologies more than doubled year-over-year, with investors prioritizing dual-use innovation that blends commercial scale with military-grade capabilities[1]. Earlier in September, the Navy's collaborative combat aircraft contracts awarded to aerospace primes demonstrated the accelerating transition from individual platforms to coordinated autonomous networks that operate seamlessly across air, land, and sea d

    9/30/25 11:53:00 AM ET
    $GSAT
    $ONDS
    $PL
    Telecommunications Equipment
    Consumer Discretionary
    Radio And Television Broadcasting And Communications Equipment
    Technology

    U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

    TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six years and older, weighing at least 40 kg  Approval was based on PROTOSTAR study, which showed pediatric patients receiving TREMFYA® achieved high levels of skin clearance vs. placebo at Week 16 HORSHAM, Pa., Sept. 29, 2025 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of children six years and older who also weigh at least 40 kg with moderate to severe plaque psoriasis (PsO), w

    9/29/25 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    $GSAT
    $IRIX
    $JNJ
    $MITK
    Leadership Updates

    Live Leadership Updates

    View All

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Concerned Vaxart Stockholders Respond to Inadequate Governance Announcements

    Believe Elevating W. Mark Watson – who Received only 56% of Votes Cast at Last Annual Meeting – to Lead Independent Director Fails to Deliver Real Reform Reiterate Intent to Vote Against Reverse Stock Split at September 19th Special Meeting ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Richard John Burgess, Daniel P. Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Mark Silverberg, DDS, MD, Matthew M. Wallace, MD and David Whitney (collectively, the "Concerned Vaxart Stockholders"), who collectively beneficially own more than 2.6 million shares of Vaxart, Inc. (OTC:VXRT) ("Vaxart" or the "Company"), today issued a statement in response to the Company's app

    9/18/25 9:00:00 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart Appoints W. Mark Watson as Lead Independent Director

    In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board's interests with stockholders Vaxart encourages all stockholders of record on July 29, 2025, who have not yet voted FOR the reverse stock split, to do so by 11:59 p.m. Eastern Time on September 18, 2025 SOUTH SAN FRANCISCO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced today that W. Mark Watson has been appointed Lead Independent Director. Mr. Watson is a Certified Public Accountant with over 50 years of experien

    9/17/25 4:05:01 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GSAT
    $IRIX
    $JNJ
    $MITK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mitek Systems Inc.

    SC 13G/A - MITEK SYSTEMS INC (0000807863) (Subject)

    11/12/24 12:48:30 PM ET
    $MITK
    Computer peripheral equipment
    Technology

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vaxart Inc (Amendment)

    SC 13G/A - Vaxart, Inc. (0000072444) (Subject)

    2/13/24 5:16:04 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GSAT
    $IRIX
    $JNJ
    $MITK
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 14th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay o

    9/3/25 4:29:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxart to Host Virtual Stockholder Fireside Chat on Wednesday, August 20 to Discuss Reverse Stock Split Proposal

    - ISS and Glass Lewis, leading independent proxy advisory firms, support reverse stock split proposal - - Webcast to begin at 4:30 p.m. ET / 1:30 p.m. PT - SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that members of the senior management team will participate in a virtual stockholder fireside chat on Wednesday, August 20, 2025 at 4:30 p.m. ET / 1:30 p.m. PT. "Our leadership team is excited for this opportunity to connect with our stockholders directly. This fireside chat is a chance for

    8/14/25 4:05:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results

    Reported positive topline data from Phase 1 clinical trial evaluating Company's second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection    Enrolled approximately 5,000 participants in COVID-19 Phase 2b trial prior to stop work order; Follow-up for all participants dosed, including 400-person sentinel cohort continues Cash, cash equivalents and investments of $26.3 million as of June 30, 2025; Current runway into 2026 Conference call today at 4:30 p.m. ET Live stockholder fireside chat scheduled on August 20, 2025 at 4:30 p.m. ET to answer frequently asked questions in advance of Special Meeting of Stockholders

    8/13/25 4:05:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care